The Dhaka Stock Exchange (DSE) has sought an explanation from Beacon Pharmaceuticals regarding why the medicine manufacturer stopped its exports abroad without issuing any disclosure on the website of the premier bourse.
The DSE informed shareholders about seeking clarification from Beacon through a disclosure yesterday.
On March 27, the Dhaka bourse sent the query to Beacon based on a news item published in The Daily Star on the same day.
Today, the drug maker issued a disclosure on the DSE website, stating:
“Beacon Pharmaceuticals PLC has always remained committed to complying with the regulatory requirements of Dhaka Stock Exchange PLC.”
“As a publicly listed company, we consistently publish our Financial Statements and Price Sensitive Information (PSI) on a quarterly basis. In addition, our Annual Report provides a comprehensive overview of the company’s financial performance, strategies, and other relevant disclosures.”
“Regarding the sale of products to Beacon Medicare Limited, we would like to confirm that such transactions are part of our strategic and technical collaborations, and they are carried out in full compliance with the applicable regulations of the Exchange,” the pharma company added.
Today, the stocks of Beacon Pharmaceuticals PLC dropped 1.97 percent to Tk 119.5 on the DSE.
